Last edition
News about "ZENBEXUS"
US FDA Grants Accelerated Approval to BMS' ZENBEXUS for Multiple Myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) ZENBEXUS, a first-in-class CELMoD therapy combined with daratumumab and dexamethasone for multiple myeloma.
ZENBEXUS | 14/08/2026 | By News Bureau
US FDA Grants Accelerated Approval to BMS' ZENBEXUS for Multiple Myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) ZENBEXUS, a first-in-class CELMoD therapy combined with daratumumab and dexamethasone for multiple myeloma.
ZENBEXUS | 14/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy